Please use this identifier to cite or link to this item:
標題: Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia
作者: Lee, W.J.
Lee, W.L.
Tang, Y.J.
Liang, K.W.
Chien, Y.H.
Tsou, S.S.
Sheu, W.H.H.
關鍵字: pravastatin;insulin sensitivity;inflammation;hypercholesterolemia;coronary-heart-disease;average cholesterol levels;c-reactive protein;cardiovascular events;statin therapy;myocardial-infarction;diabetes-mellitus;controlled-trial;cd40 ligand;glucose
Project: Clinica Chimica Acta
期刊/報告no:: Clinica Chimica Acta, Volume 390, Issue 1-2, Page(s) 49-55.
Background: Statins may improve lipid profiles and inflammation-associated biomarkers, but the effect on insulin sensitivity is controversial. We investigated the effects of 2 doses of pravastatin (40 and 10 mg/day) on insulin sensitivity and serum inflammatory markers in nondiabetic hypercholesterolemic patients. Methods: This was a randomized, parallel, comparative design study. A total of 40 nondiabetic subjects with elevated low-density lipoprotein (LDL) cholesterol were randomized to either the 40 mg pravastatin/day group (n =21) or the 10 mg pravastatin/day group (n=19) for 8 weeks. The fasting serum lipid profile, homeostasis model assessment (HOMA), glucose and insulin response of the two-hour glucose tolerance test (2 h-OGTT), and several inflammatory markers were determined. Results: Eight weeks of pravastatin treatment in both dose groups led to a significant reduction in serum LDL cholesterol, total cholesterol, triglycerides, and total cholesterol/high-density lipoprotein (HDL) cholesterol ratios (all p<0.01 in 40 mg group and all p<0.05 in 10 mg group), though the 40 mg group had greater effects. Although the fasting HOMA insulin resistance did not change significantly in either group, glucose and insulin areas under the curve of 2 h-OGTT were significantly decreased, suggesting improvement in insulin sensitivity post glucose challenge. Serum CD-40 ligand concentration was significantly reduced in the 40 mg pravastatin/day group and soluble P-selectin significantly reduced in both groups. Conclusions: Pravastatin treatment, at 10 mg or 40 mg daily for 8 weeks, reduced serum lipids and some inflammatory markers in nondiabetic hypercholesterolemic subjects. Furthermore, insulin resistance was improved even in short-teen treatment by pravastatin. (C) 2008 Elsevier B.V. All rights reserved.
ISSN: 0009-8981
DOI: 10.1016/j.cca.2007.12.013
Appears in Collections:期刊論文

Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.